Last reviewed · How we verify
rHuEPO
rHuEPO (recombinant human erythropoietin) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.
rHuEPO (recombinant human erythropoietin) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in HIV-infected patients receiving zidovudine therapy.
At a glance
| Generic name | rHuEPO |
|---|---|
| Also known as | rHuEPO group, Recombinant Human Erythropoietin Injection |
| Sponsor | Amgen |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
rHuEPO is a recombinant version of the naturally occurring hormone erythropoietin (EPO), which regulates red blood cell production in the bone marrow. By activating the EPO receptor on erythroid progenitor cells, it promotes their proliferation and differentiation into mature red blood cells. This mechanism is used therapeutically to treat anemia by increasing hemoglobin and hematocrit levels.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in HIV-infected patients receiving zidovudine therapy
- Perioperative anemia in patients undergoing elective surgery
Common side effects
- Hypertension
- Headache
- Arthralgias
- Fatigue
- Thrombotic events (stroke, MI, DVT)
- Pure red cell aplasia
Key clinical trials
- Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis (PHASE4)
- Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients (PHASE4)
- Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis (PHASE4)
- Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies (PHASE2)
- Effect of the Combined Programme on Perioperative Anaemia（CPPA） (NA)
- Identifying Biological Markers for Altitude Exposure and Use of Recombinant Human Erythropoietin (rHuEPO) (NA)
- Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis (PHASE3)
- A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rHuEPO CI brief — competitive landscape report
- rHuEPO updates RSS · CI watch RSS
- Amgen portfolio CI